By Sabela Ojea
BridgeBio Pharma said it is fully financed to launch its cardiomyopathy treatment Attruby and read out its phase 3 clinical trials, which are fully enrolled.
Shares rose 8.6% to $31.58 in morning trading. The stock has, however, fallen 20% over the past 12 months.
The biotechnology company on Monday said that since the Food and Drug Administration approved Attruby in November, the treatment has been prescribed to 430 patients by 248 physicians.
BridgeBio Pharma also said it expects $105 million in regulatory milestones from acoramidis - sold under the brand name Attruby - approvals in Europe and Japan in the first half of the year, and that it received $500 million upon the FDA's drug acoramidis approval from royalty facility
Overall in the latest quarter, the company had $406 million in cash, BridgeBio Pharma added.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 13, 2025 11:46 ET (16:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.